RxDoctor Payments Data

Abel Gonzalez, MD

Internal Medicine · West Orange, NJNPI 1568711448

Payments from drug & device makers

$21,444in general payments, 2019–2025

Across 1,447 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Boehringer Ingelheim$1K
  • Amgen$1K
  • AstraZeneca$1K
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$21,360100%
  • Education$840%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk281$3,668
AbbVie(2 entities)132$1,819
Lilly USA, LLC107$1,662
Boehringer Ingelheim94$1,298
Amgen(2 entities)84$1,200
AstraZeneca71$1,149
Merck62$900
Pfizer60$842
Bayer49$827
Novartis51$659
Sanofi-aventis U.S. LLC36$648
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC42$606
Amarin Pharma, Inc.40$579
Kowa Pharmaceuticals America, Inc.32$458
Ardelyx, Inc.24$424
Corcept Therapeutics23$409
Dexcom, Inc.22$387
Exact Sciences14$382
Johnson & Johnson21$322
Idorsia Pharmaceuticals US Inc19$283
Astellas Pharma US Inc12$230
GSK15$225
Azurity Pharmaceuticals, Inc.12$204
Xeris Pharmaceuticals, Inc.12$198
Daiichi Sankyo Inc.13$185
Scilex Pharmaceuticals Inc.12$167
Hikma Pharmaceuticals USA8$115
Ironwood Pharmaceuticals, Inc8$103
Abbott5$102
E.r. Squibb & Sons, L.L.C.6$94
Intra-sana Laboratories6$91
Gilead4$79
Biohaven Pharmaceutical Holding Company Ltd.5$71
UCB, Inc.4$71
Nestle Healthcare Nutrition Inc.5$70
Antares Pharma, Inc.4$70
Lundbeck LLC4$68
Esperion Therapeutics, Inc.4$63
Almatica Pharma LLC4$62
Takeda Pharmaceuticals U.S.A., Inc.4$61
Otsuka America Pharmaceutical, Inc.3$56
Axsome Therapeutics, Inc.2$49
Sanofi Pasteur Inc.3$48
Eisai Inc.3$43
Genentech USA, Inc.3$40
Insulet Corporation2$40
Nabriva Therapeutics, PLC3$38
Aimmune Therapeutics, Inc.2$34
Boston Scientific1$32
Phathom Pharmaceuticals, Inc.2$31
Arbor Pharmaceuticals, Inc.2$30
Biohaven Pharmaceuticals, Inc.2$26
Phadia US Inc.1$19
Medtronic1$19
Currax Pharmaceuticals LLC1$17
Amphastar Pharmaceuticals, Inc.1$17
Eyevance Pharmaceuticals LLC1$15
Vanda Pharmaceuticals Inc.1$15
Teva Pharmaceuticals USA, Inc.1$13
Metuchen Pharmaceuticals1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,444 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,590
Medicare patients
173
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide203$291,630
OzempicSemaglutide160$230,091
JardianceEmpagliflozin144$167,132
RybelsusSemaglutide37$82,386
JanuviaSitagliptin Phosphate62$70,069
FarxigaDapagliflozin Propanediol75$65,733
EliquisApixaban48$62,226
OtezlaApremilast12$58,974
LinzessLinaclotide59$48,836
TrulicityDulaglutide33$43,571
VascepaIcosapent Ethyl44$21,811
JanumetSitagliptin Phos/Metformin Hcl15$19,606
Repatha SureclickEvolocumab11$16,675
Soliqua 100-33Insulin Glargine/Lixisenatide16$15,862
TradjentaLinagliptin21$13,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,662$335,201236 claims
Novo NordiskOzempic, Rybelsus$3,668$312,478197 claims
Boehringer IngelheimJardiance, Tradjenta$1,298$181,032165 claims
MerckJanuvia, Janumet$900$89,67577 claims
AstraZenecaFarxiga$1,149$65,73375 claims
PfizerEliquis$842$62,22648 claims
AmgenOtezla$1,200$58,97412 claims
AbbVieLinzess, Synthroid$1,819$51,08676 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$648$15,86216 claims
GSKTrelegy Ellipta, Breo Ellipta$225$14,83728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →